News Sharing
For sharing news, please enter the email address of you and the receiver, then press SEND button.*Mandatory Fields
Receiver*
Enter email addresses, separated by semicolon (;). E.g. a@a.com;b@b.com
Your email address*
 Content Sharing
石四藥(02005.HK)治療不穩定心絞痛注射藥物獲批生產註冊
石四藥(02005.HK)公布，已取得國家藥監局有關注射用Diltiazem Hydrochloride (10mg)的藥品生產註冊批件，屬於化學藥品第4類，視同通過一致性評價。該藥主要用於室上性心動過速、手術時異常高血壓的急救處置、高血壓急症及不穩定心絞痛。 此外，集團亦已取得國家藥監局有關Propranolol Hydrochloride Injecti...
Reset
Send
The window will close in 5 seconds
石四藥(02005.HK)治療不穩定心絞痛注射藥物獲批生產註冊
Close
Recommend
1
Positive
0
Negative
0
 
SHORT SELL
 
STOCK INFO
aacat by AASTOCKS
Open a new trading account to get Level 1 Real-Time Streaming!

石四藥(02005.HK)  +0.060 (+2.620%)    Short selling $1.45M; Ratio 62.805%   公布，已取得國家藥監局有關注射用Diltiazem Hydrochloride (10mg)的藥品生產註冊批件，屬於化學藥品第4類，視同通過一致性評價。該藥主要用於室上性心動過速、手術時異常高血壓的急救處置、高血壓急症及不穩定心絞痛。

此外，集團亦已取得國家藥監局有關Propranolol Hydrochloride Injection (5ml: 5mg及2ml: 2mg)，屬於化學藥品第3類，視同通過一致性評價。該注射液主要用於控制室上性快速心律失常及室性心律失常、勞力型心絞痛及嗜鉻細胞瘤(配合α受體阻滯劑用於控制心動過速)。而集團的Propranolol Hydrochloride原料藥已獲國家藥監局批准登記成為在上市製劑使用的原料藥。(hc/j)(HK stocks quote is delayed for at least 15 mins.Short Selling Data as at 2026-05-04 16:25.)

AASTOCKS新聞

Switch to Auto-Translated Version
Copyright(C) AASTOCKS.com Limited 2000. All rights reserved.
Disclaimer: AASTOCKS.com Ltd, HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the Information provided but do not guarantee its accuracy or reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.